Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.
about
Acquired pure red cell aplasia: updated review of treatmentAnalytics of nonpeptidic erythropoietin mimetic agents in sports drug testing employing high-resolution/high-accuracy liquid chromatography-mass spectrometry.Lipid, blood pressure and kidney update 2013.The role of anemia management in improving outcomes for African-Americans with chronic kidney diseaseMethods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor.A screen for peptide agonists of the G-CSF receptorSynthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes.An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients.Erythropoietin after a century of research: younger than ever.Effects of Peginesatide Injection on QTc Interval in Healthy Adults.Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients.Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis.Erythropoietic agents and the elderly.CERA: third-generation erythropoiesis-stimulating agent.Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS).Chronic pharmacological and safety evaluation of Hematide, a PEGylated peptidic erythropoiesis-stimulating agent, in rodents.Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide.Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis.Erythropoietic stimulating agents.Erythropoietin receptor response circuitsPeginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.Hematide™ for the treatment of chronic kidney disease-related anemia.Recent developments in doping testing for erythropoietin.Detection of erythropoiesis-stimulating agents in human anti-doping control: past, present and future.Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.Peginesatide for the treatment of renal disease-induced anemia.Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Treatment of anemia in chronic kidney disease: known, unknown, and both.EPOR-Based Purification and Analysis of Erythropoietin Mimetic Peptides from Human Urine by Cys-Specific Cleavage and LC/MS/MS.Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia.Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in ratsAnaemia: The safety and efficacy of peginesatide in patients with CKD."Bio"-macromolecules: polymer-protein conjugates as emerging scaffolds for therapeutics.A subchronic murine intravenous pharmacokinetic and toxicity study of Hematide™, a PEGylated peptidic erythropoiesis-stimulating agent.Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers.Emerging drugs: mechanism of action, mass spectrometry and doping control analysis.Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice.Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide administration in cynomolgus monkeys.
P2860
Q24652253-8F5F7F9C-7EF4-49B2-92DF-C61A06DE933AQ30390786-9A87DDF4-71CF-4F09-B490-CC5CEFF3BE01Q33574532-27CCAC40-0814-4D7C-AC42-0636E1A24AAEQ33646679-C349CC86-1292-45FD-A364-12663D0F8F51Q33655344-111FD8D2-D0C7-4D4C-9EE7-2CF9B19677BEQ33933699-0F709019-5C03-42E2-80E6-FAFF24E2EDDCQ33944531-42B6827A-5064-4FFA-943D-7CF686141F87Q34398392-EB3AE38D-6553-4011-B6C8-90A07AAF4F09Q34606348-A08E6CA8-F38F-4796-A9FA-F9F61C869658Q35810325-6E4A3C5D-D62B-44F0-A762-43C9362C52C8Q35985899-5F82AFB0-0D75-4270-A264-F0DFF948766FQ36039649-11AA16F8-A077-4CAC-8FDB-0F011B6F159EQ37098040-244E3912-3DD7-4794-AF42-85D28A964557Q37111869-86137953-FCA5-435B-92FB-BF56E214E2A2Q37113720-D2C53B35-D666-4C64-80E2-20F8C578EF01Q37154338-4603E3AC-205A-4CB1-BA97-FDBC7392B5E3Q37157237-0C1B68C3-FF56-42ED-A8DF-E3FB7E6AA3E6Q37359343-A6B3CC0C-1758-4E36-B81B-FB950FAEB190Q37693160-00F5C4FB-8214-4D98-A115-23097B655CD2Q37696206-6DFD7B14-9C78-4AD9-9E7A-9F0EBEF45BB1Q37700912-106FEA3B-DD4E-46C4-A42E-8E319A97A2DFQ37810076-53BBCA19-0BB8-4B10-9BDA-9A3BF44D9132Q37884431-08181E5A-C5C7-4E45-A420-F167C4C15373Q38029405-0B10156A-ED15-4EC2-AB2C-05EDAE34C820Q38075798-51A05EF5-FA37-4745-BC07-49F9C7304FCFQ38090725-BDFB0CC4-C54C-4D09-BD6E-EF1070D18C82Q38126361-8A4616B5-E39B-4B35-8359-8E3408758296Q40540575-9E977AAE-4C12-4CF2-A8DC-A9C7C17CE0C9Q40785295-6748F023-3ED8-45C6-A77A-F4940F9D33A8Q41892226-C8EDDFAB-F5DF-437D-9377-D7876C27CB95Q42257325-B75F11B3-A019-4BA4-B3C6-F211995D5B51Q44067854-8E69FB29-2CD5-4BFD-BCEA-FD6BF84C4CD2Q46335892-E1FCDEBB-F8C9-45DD-815F-EC354A7F0456Q46807825-B6A23DBC-A4A9-4F24-A845-9D7F009012B1Q46891656-F27D5530-6408-45D0-A115-08B023C76F91Q47992683-6591155E-8F25-4CEA-BCE8-FD815F8545B4Q50041581-B773CDD3-CE98-4F82-8AE1-5791F531A55EQ50581034-5D90B8F1-BE07-4A7A-8061-E70FF2905007
P2860
Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Evaluation of the safety and p ...... n study in healthy volunteers.
@ast
Evaluation of the safety and p ...... n study in healthy volunteers.
@en
Evaluation of the safety and p ...... n study in healthy volunteers.
@nl
type
label
Evaluation of the safety and p ...... n study in healthy volunteers.
@ast
Evaluation of the safety and p ...... n study in healthy volunteers.
@en
Evaluation of the safety and p ...... n study in healthy volunteers.
@nl
prefLabel
Evaluation of the safety and p ...... n study in healthy volunteers.
@ast
Evaluation of the safety and p ...... n study in healthy volunteers.
@en
Evaluation of the safety and p ...... n study in healthy volunteers.
@nl
P2093
P1433
P1476
Evaluation of the safety and p ...... on study in healthy volunteers
@en
P2093
Anne-Marie Duliege
Dawie Wessels
Douglas M Okamoto
John Lambert
Julie S Iwashita
Kerstin K Leuther
Peter J Schatz
Richard B Stead
Robert Naso
P304
P356
10.1182/BLOOD-2006-04-015818
P407
P577
2006-05-23T00:00:00Z